Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7201–7250 of 34735
On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.
On August 29, 2024, the Board of Directors (the "Board") of Kentucky First Federal Bancorp (the "Company") appointed R. Clay Hulette as a director of the Company, effective August 29, 2024, for an initial term expiring at the 2024 annual meeting of stockholders or until his successor shall have been duly elected and qualified.
Mr. Hulette's appointment will fill the vacancy created by the recent retirement of Tony D. Whitaker from the Board of Directors of the Company.
On August 28, 2024, Mr. Matthew Barger notified iLearningEngines, Inc. (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and all committees thereof.
the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.
the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.
the Board of Directors of the Company appointed Chris D. Reece to the Board of Directors of the Company.
the Board also increased the size of the Board from eight to nine members and appointed Mr. Marotta as a member of the Board
appointed Brock J. Pierce as a Class II director to the Board, with a term expiring at the Company’s annual meeting of stockholders in 2025.
Mr. Lanni was also elected to serve as a director of the Company to fill the vacancy created by Mr. Schreiber’s resignation.
appointed Fiona Tan to the Board as a Class III director and as a member of the Audit Committee of the Board, effective October 14, 2024.
appointed Timothy Baxter to the Board as a Class II director and as a member of the Compensation Committee of the Board, effective October 14, 2024.
Steve Anderson notified the Company of his decision to resign from the Company's Board, effective September 6, 2024.
On September 2, 2024, Tamar Yehoshua notified the board of directors (the “Board”) of the Company of her intention to resign as a member of the Board, effective at the end of the day on September 13, 2024.
On August 30, 2024 the Board of Directors of Insight Enterprises, Inc. (the “Company”) voted to increase the size of the Company’s Board of Directors from 10 to 12 members and elect Janet Foutty and Thomas Reichert as members of the Company’s Board of Directors
On August 30, 2024 the Board of Directors of Insight Enterprises, Inc. (the “Company”) voted to increase the size of the Company’s Board of Directors from 10 to 12 members and elect Janet Foutty and Thomas Reichert as members of the Company’s Board of Directors
On August 28, 2024, we certified the election by our member, Columbus Electric Cooperative, Inc., of Zane Shanon Nunn to replace Chris Martinez, as the director representing them on our Board of Directors.
On August 28, 2024, we certified the election by our member, Columbus Electric Cooperative, Inc., of Zane Shanon Nunn to replace Chris Martinez, as the director representing them on our Board of Directors.
the Board of Directors (the "Board") unanimously appointed Lisa Campbell as a Class III director, effective on September 4, 2024.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
each of Dale S. Rosenthal, Michael S. Della Rocca, Edward A. Ryan and David M. Sparby (collectively, the “Prospective Everus Construction Directors”) are expected to resign as directors of the Company
each of Dale S. Rosenthal, Michael S. Della Rocca, Edward A. Ryan and David M. Sparby (collectively, the “Prospective Everus Construction Directors”) are expected to resign as directors of the Company
each of Dale S. Rosenthal, Michael S. Della Rocca, Edward A. Ryan and David M. Sparby (collectively, the “Prospective Everus Construction Directors”) are expected to resign as directors of the Company
each of Dale S. Rosenthal, Michael S. Della Rocca, Edward A. Ryan and David M. Sparby (collectively, the “Prospective Everus Construction Directors”) are expected to resign as directors of the Company
On September 3, 2024, Clean Harbors, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from eleven to thirteen members and the election of Co-Chief Executive Officers Michael Battles and Eric Gerstenberg to the Board, all effective immediately following the Company's board meeting on August 29, 2024.
On September 3, 2024, Clean Harbors, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from eleven to thirteen members and the election of Co-Chief Executive Officers Michael Battles and Eric Gerstenberg to the Board, all effective immediately following the Company's board meeting on August 29, 2024.
On September 3, 2024, Hawthorn Bancshares, Inc. (the "Company") announced that Bob Regnier has been elected to serve on both the Company's and Hawthorn Bank's board of directors as a non-voting advisory director, effective immediately.
On August 28, 2024, Michael J. Fox notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective on August 28, 2024.
voted to increase the size of the Board from 11 members to 12 members and to elect Ms. Nelda J. Connors to the Board of the Company
On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.
On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.
On August 27, 2024, Ali Behbahani gave notice of his intention to resign from the Board effective at the close of business on September 2, 2024.
On August 29, 2024, based on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Emeren Group Ltd. (the “Company”), the Board appointed Ramakrishnan Srinivasan as a director, effective September 1, 2024.
Curtis McWilliams and Adam Markman have tendered their resignations from the board of directors
the Board appointed Christopher R. Gingras to serve as a director on the Board
Curtis McWilliams and Adam Markman have tendered their resignations from the board of directors
On August 27, 2024, Robert Bernshteyn was appointed to the Board of Directors of PTC Inc., effective as of September 9, 2024.
When the election of Messrs. Raanan I. Horowitz, Adrian Zuckerman, Darius Moshfeghi and Ms. Karen Rogge as directors of the Company became effective on August 30, 2024, each of them entered into an indemnity agreement with the Company.
When the election of Messrs. Raanan I. Horowitz, Adrian Zuckerman, Darius Moshfeghi and Ms. Karen Rogge as directors of the Company became effective on August 30, 2024, each of them entered into an indemnity agreement with the Company.
When the election of Messrs. Raanan I. Horowitz, Adrian Zuckerman, Darius Moshfeghi and Ms. Karen Rogge as directors of the Company became effective on August 30, 2024, each of them entered into an indemnity agreement with the Company.
When the election of Messrs. Raanan I. Horowitz, Adrian Zuckerman, Darius Moshfeghi and Ms. Karen Rogge as directors of the Company became effective on August 30, 2024, each of them entered into an indemnity agreement with the Company.
On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.
Treasure Global Inc (the “Company”) appointed (i) Leong Wei Ping as a member of the Board of Directors of the Company (“Board”), as Chairman of the Audit Committee of the Board (“Audit Committee”), a member of the Nominating and Corporate Governance Committee of the Board (“Nominating and Corporate Governance Committee”) and a member of the Compensation Committee of the Board (“Compensation Committee”), effective as of August 29, 2024
On August 27, 2024, the Board of Directors (the “Board”) of Sidus Space, Inc. (the “Company”) appointed Lavanson C. “LC” Coffey III as a director, effective immediately, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.
On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.
On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.
On August 28, 2024, Mr. Bryan Capelli resigned his position as a Director of the Corporation.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.